Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T-cell lymphoma
PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics Inc., a clinical-stage immunotherapy company specializing in the development of innovative therapies for hard-to-treat diseases, today announced it will present a trials-in-progress poster highlighting the ongoing Phase 1 clinical trial of VIPER-101, the Company’s lead investigational CD5-targeted CAR-T therapy for relapsed/refractory T-cell lymphoma, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30 – June 3, 2025 in Chicago, Illinois.
The presentation will feature the design and objectives of the Phase 1 study, which marks the first clinical application of Vittoria’s proprietary Senza5™ platform — a next-generation CAR-T engineering and manufacturing approach that incorporates CD5 modulation to enhance cell potency, durability, and safety.
The open-label Phase 1 study is designed to assess safety and preliminary efficacy, and to determine the recommended Phase 2 dose (RP2D) of VIPER-101 in patients with relapsed or refractory CD5 positive T-cell non-Hodgkin lymphoma (NHL). The study is currently recruiting patients and additional information can be found at ClinicalTrials.gov (NCT06420089). Details on the poster presentation can be found below:
Presentation Details
Title: A Phase 1 Study of VIPER-101, a CD5 Knockout, CD5-Targeted, Autologous CAR-T Cell Therapy for the Treatment of Relapsed or Refractory T-Cell Lymphoma
Abstract Number: TPS7087
Session Track: Hematological Malignancies
Presentation Type: Trials-in-Progress Poster
Date/Time: Sunday, June 1, 2025 | 9:00 AM CT
Location: Hall A | Poster Board #268a
About VIPER-101
VIPER-101 is a gene-edited, autologous, dual-population cell therapy being evaluated as a potential treatment for patients with T-cell lymphoma. VIPER-101 is designed to target CD5, which is present on cancer cells in more than 85% of patients with T-cell lymphoma. VIPER-101 leverages the company’s proprietary Senza5 platform technology, which enhances T cell effector function by abrogating CD5-mediated immunosuppression through gene editing. In preclinical studies, VIPER-101 has shown superior efficacy compared to classical CD5-targeted CAR T.
About Senza5™
Senza5™ is a proprietary cell therapy engineering and manufacturing platform that combines the power of genetic engineering and a proprietary five-day manufacturing process to maximize stemness, durability, and efficacy of its produced cell therapies by disabling the CD5 signaling pathway on engineered CAR T cells and bypassing CD5's immunosuppressive effects to amplify the therapy’s antitumor activity. The expedited five-day manufacturing process further enhances stemness, which promotes greater in vivo expansion and durability and the potential for longer-lasting responses. Senza5 can be widely utilized to improve the efficacy of engineered T-cell therapies by acting on the fundamental biology of T cells.
About Vittoria Biotherapeutics
Vittoria Biotherapeutics, Inc., a clinical-stage cell therapy company, is developing novel CAR T-cell therapies that transcend the limitations of current cell therapies. Based on technology exclusively licensed from the University of Pennsylvania, the Company’s proprietary Senza5™ platform unlocks the cytotoxic potential of engineered T cells and utilizes a five-day manufacturing process to maximize stemness, durability, and potency. By acting on the fundamental biology of T cells, Senza5 can be used to improve the efficacy of engineered T-cell therapies with pipeline applications in oncology and autoimmune diseases. To learn more, visit vittoriabio.com and follow us on LinkedIn.
Investor Contact
Vittoria Biotherapeutics, Inc.
Nicholas A. Siciliano, Ph.D.
Chief Executive Officer
+1 215-600-1380
Media Contact
LifeSci Communications
Jason Braco, Ph.D.
jbraco@lifescicomms.com
+1 646-876-4932
